Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx

This article was originally published in The Pink Sheet Daily

Executive Summary

Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.


Related Content

Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts